What Oncodesign Services does

Oncodesign Services is a private contract research organization (CRO) headquartered in Dijon, France, specializing in preclinical drug discovery and translational pharmacology, primarily for oncology and inflammation. Founded in 1995/1996, the company operates approximately 280 employees across four countries (France, the Netherlands, the United States, and Canada) and reported €44 million in revenue following its January 2024 acquisition of Dutch biophysics CRO ZoBio, funded by a €22 million minority investment from Eurazeo's Nov Santé Actions Non Cotées fund.

The company's core technology stack spans the full preclinical workflow: structural biology (SPR, NMR, TINS, cryo-EM via ZoBio), medicinal chemistry (small molecules, PROTACs, fragments), in vitro biology, DMPK, bioanalysis, bioconjugation/radiochemistry for molecular radiotherapy (MRT), in vivo pharmacology, and pharmaco-imaging. Its proprietary in-house portfolio of more than 500 characterized tumor models (PDX, CDX, syngeneic) across 20 organ origins, together with humanized mouse models for immuno-oncology and GLP-compliant facilities with AAALAC International accreditation, constitutes a deeply specialized translational research engine. Service offerings are packaged into integrated branded solutions—EXPLORE (target ID/validation), DRIVE-IDDS (hit-to-lead across modalities), INPACT (preclinical pharmacology), SOLO (technical platform access), and D-VLOP (IND-enabling work)—alongside discrete therapeutic area services in oncology, inflammation, microbiome, and infectious disease (BSL2/BSL3).

Revenue is generated through project-based, long-term professional services contracts with pharmaceutical and biotechnology companies, delivered via direct enterprise field sales with dedicated project leaders as single points of contact. Pricing is not publicly disclosed and is quote-based per project scope. Customer segments are primarily large pharma and biotech companies (with academic/research institutions as a secondary segment), and go-to-market emphasizes scientific expertise and integrated workflow selling. Recent strategic moves signal a deliberate pivot into radiopharmaceuticals (Debiopharm and GIP ARRONAX collaborations) and continued internationalization, while consecutive "Oncology CRO of the Year – France" awards in 2024 and 2025 reflect brand strength in translational oncology.

Name

Oncodesign Services

Legal name

Oncodesign Services

Website

https://oncodesign-services.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

101–250 employees

Short description

Oncodesign Services is a private French CRO providing integrated preclinical drug discovery and translational pharmacology services—spanning biophysics, medicinal chemistry, in vivo pharmacology, tumor models, and radiopharmaceuticals—to pharmaceutical and biotechnology companies across Europe and North America.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services (Drug Discovery CRO)

NAICS

Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Preclinical drug discovery
• Contract research services
• Oncology translational pharmacology
• Radiopharmaceutical development
• In vivo pharmacology services

Headquarters

HQ city

Dijon

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Preclinical Contract Research Services: Oncodesign Services generates revenue through providing contract research organization (CRO) services for drug discovery and preclinical development. Services span target identification, hit-to-lead, lead optimization, in vitro/in vivo pharmacology, bioanalysis, DMPK, and regulatory filing support (IND). Revenue is project-based, typically long-term contracts with pharmaceutical and biotechnology companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Oncodesign Services is a contract research organization (CRO) that provides integrated preclinical drug discovery services for pharmaceutical and biotechnology clients. Its offerings span target identification and validation, medicinal chemistry, in vitro and in vivo pharmacology, DMPK, bioanalysis, bioconjugation/radiochemistry, and IND-enabling work, with oncology, inflammation, infectious disease, and microbiome as primary therapeutic areas. Deliverables are delivered as customized research programs through dedicated project leaders from laboratories in France, the Netherlands, Canada, and the United States.

Product overview

Oncodesign Services is a Contract Research Organization (CRO) specializing in drug discovery and preclinical services, offering integrated solutions from target identification to IND filing. The portfolio includes Discovery Services (Structural Biology, Medicinal Chemistry, In Vitro Biology, DMPK, Bioanalysis, Bioconjugation/Radiochemistry, In Vivo Pharmacology, and Pharmaco-Imaging), Integrated Solutions (EXPLORE for target ID/validation, DRIVE-IDDS for integrated drug discovery, INPACT for preclinical pharmacology, SOLO for technical platforms, and D-VLOP for IND filing), and specialized therapeutic area services in Oncology (Tumor Models, PDX, CDX, Humanized Models, Immuno-Oncology, MRT) and Inflammation (IBD, Dermal, Endometriosis, Autoimmunity, GvHD, CNS, and other organ-specific models). The company also provides Microbiome and Infectious Disease services, with ZoBio providing biophysics capabilities following its 2024 acquisition.

Differentiator

Problem solved

Functional benefit

Products and services

• EXPLORE (Target Identification and Validation)
• DRIVE-IDDS (Integrated Drug Discovery Solution)
• INPACT (Preclinical Pharmacology Integrated Services)
• SOLO (Innovative Technical Platforms)
• D-VLOP (Drug to IND Filing)
• Structural Biology Services
• Medicinal Chemistry
• In Vitro Biology
• DMPK (Drug Metabolism and Pharmacokinetics)
• Bioanalysis, Formulation, Immunogenicity and Biomarkers
• Bioconjugation and Radiochemistry Platform
• In Vivo Pharmacology
• Pharmaco-Imaging (In Vivo Imaging)
• Oncology Immuno-Oncology Services
• Oncology Tumor Models
• Orthotopic Tumor Models
• Metastatic Tumor Models
• Humanized Mouse Models
• Radiopharmaceutical Development (MRT)
• Autoimmunity Models
• Dermal Inflammation Models
• Endometriosis Models
• IBD Models
• Kidney Inflammation Models
• Liver Inflammation Models
• Lung Inflammation Models
• Systemic Inflammation Models
• CNS Inflammation Models
• Microbiome Services
• ZoBio Biophysics Platform
• Infectious Disease Preclinical Services

Quantifiable outcome

• Successfully developed several drug candidates that have reached clinical development phase together with partner clients
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Four partnerships are on record, tiered important, major, supporting and core.

• GIP ARRONAXimportantStrategic or Co-development Partner · 13 April 2026Extended collaboration with GIP ARRONAX to strengthen access to astatine-211 (At-211) supply for targeted alpha radiotherapy programs. GIP ARRONAX provides access to this critical radioisotope used in molecular radiotherapy development.
• DebiopharmmajorStrategic or Co-development Partner · 24 April 2025Strategic collaboration between Debiopharm and Oncodesign Services to advance radiopharmaceuticals in preclinical research. The partnership focuses on leveraging Oncodesign Services' molecular radiotherapy platform and expertise in radiopharmaceutical development.
• Medicen Paris RegionsupportingStrategic or Co-development Partner · 1 February 2024Oncodesign Services participated in the Medicen 'Microbiome Drug Metabolism' working group, led by Patrick Jimonet. Sylvie Maubant from Oncodesign Services co-led the 'In vivo' working group. The collaboration produced a comprehensive review published in Drug Metabolism and Disposition journal, with over 30 international experts contributing proposals for integrating microbiome considerations in drug discovery.
• ZoBiocoreStrategic or Co-development Partner · 1 January 2024ZoBio, a boutique CRO based in Leiden, Netherlands specializing in biophysics-based drug discovery, was acquired by Oncodesign Services in 2024. ZoBio brings capabilities including biophysical and functional assays, protein production, structural biology (crystallography, NMR, cryo-EM), and fragment-focused medicinal chemistry.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Reaction Biology: Specialty discovery CRO offering biophysics, biochemistry, and in vitro pharmacology services to pharma and biotech. Comparable to Oncodesign through its biophysics capabilities acquired with ZoBio, with overlap in SPR, NMR-based assay development.
• HD Biosciences: Mid-sized preclinical CRO offering in vitro and in vivo pharmacology, immuno-oncology, and disease models. Comparable to Oncodesign in therapeutic-area focus, integrated preclinical offerings, and client base of pharma/biotech sponsors.
• Crown Bioscience: Specialty preclinical oncology CRO with extensive PDX, CDX and humanized mouse model portfolios serving pharma and biotech sponsors. Closely comparable to Oncodesign on therapeutic-area focus (oncology), in vivo pharmacology capabilities, and translational model depth.

Broad incumbents

• Evotec: Integrated drug discovery CRO offering target ID through preclinical services, including partnerships in oncology and radiopharmaceuticals. Comparable to Oncodesign in providing integrated discovery platforms, though broader in scope and modality coverage.
• Eurofins Discovery: Discovery services arm of Eurofins Scientific offering medicinal chemistry, in vitro pharmacology, ADME, and in vivo services. Comparable to Oncodesign in integrated preclinical offerings with broader test menu and larger scale across multiple geographies.
• WuXi AppTec: Global CRO/CDMO offering discovery, preclinical, and clinical services with very large scale. Comparable to Oncodesign across preclinical pharmacology, DMPK, and bioanalysis, with much broader geographic reach and integrated development services.
• Pharmaron: Full-service CRO providing drug discovery, DMPK, bioanalysis, and in vivo pharmacology across multiple therapeutic areas. Overlaps with Oncodesign across integrated discovery, bioanalysis, and preclinical model capabilities, with a broader China-rooted footprint.
• GenScript ProBio: Biotechnology services provider offering biologics discovery, cell therapy, and preclinical services including tumor models and bioanalysis. Comparable to Oncodesign across biologics discovery, bioanalysis, and oncology in vivo services with broader CDMO exposure.
• Charles River Laboratories: Global preclinical CRO offering discovery, safety assessment, and manufacturing services across multiple therapeutic areas. Overlaps with Oncodesign in preclinical in vivo pharmacology, oncology models, and DMPK/bioanalysis but operates at materially larger scale.

Regional players

• Bienta (Enamine): Preclinical CRO based in Ukraine/Europe offering integrated drug discovery, in vivo pharmacology, and bioanalysis services. Comparable to Oncodesign in integrated preclinical offerings and European pharma/biotech customer base, though with a different geographic footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/oncodesignODS
• LinkedInlinkedin.com/company/oncodesign

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncodesign Services